Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Insmed Incorporated - Common Stock
(NQ:
INSM
)
148.31
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 25, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
346
Open
148.31
Bid (Size)
142.49 (100)
Ask (Size)
149.50 (300)
Prev. Close
148.31
Today's Range
148.31 - 148.31
52wk Range
60.40 - 212.75
Shares Outstanding
115,246,666
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
↗
March 21, 2026
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
↗
March 21, 2026
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
Via
The Motley Fool
Topics
Regulatory Compliance
Performance
YTD
-16.3%
-16.3%
1 Month
-6.7%
-6.7%
3 Month
-16.4%
-16.4%
6 Month
+5.2%
+5.2%
1 Year
+88.8%
+88.8%
More News
Read More
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
↗
March 20, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
↗
March 20, 2026
Via
The Motley Fool
The Small-Cap Renaissance: Why the Russell 2000 is Leading the Charge in 2026
March 09, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Supply Chain
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
↗
March 03, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
↗
March 02, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
↗
March 02, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year
↗
February 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50%
↗
February 23, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Insmed (INSM) Q4 2025 Earnings Call Transcript
↗
February 19, 2026
Via
The Motley Fool
Topics
Earnings
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition
↗
February 17, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
↗
February 17, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge
↗
February 17, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Up 266%: This New $55 Million Bet Signals Conviction in Praxis Amid Pipeline Progress
↗
February 14, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Apogee Stock Jumps 87% in One Year as This Biotech Fund Lifts Stake to $93 Million
↗
February 14, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
January 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
January 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib
↗
January 06, 2026
Via
The Motley Fool
Topics
Stocks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
January 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
December 30, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm
December 29, 2025
From
The Schall Law Firm
Via
Business Wire
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line
↗
December 28, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit
↗
December 17, 2025
Via
Stocktwits
Wondering what's happening in today's after-hours session?
↗
December 17, 2025
Via
Chartmill
Frequently Asked Questions
Is Insmed Incorporated - Common Stock publicly traded?
Yes, Insmed Incorporated - Common Stock is publicly traded.
What exchange does Insmed Incorporated - Common Stock trade on?
Insmed Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Insmed Incorporated - Common Stock?
The ticker symbol for Insmed Incorporated - Common Stock is INSM on the Nasdaq Stock Market
What is the current price of Insmed Incorporated - Common Stock?
The current price of Insmed Incorporated - Common Stock is 148.31
When was Insmed Incorporated - Common Stock last traded?
The last trade of Insmed Incorporated - Common Stock was at 03/25/26 04:00 PM ET
What is the market capitalization of Insmed Incorporated - Common Stock?
The market capitalization of Insmed Incorporated - Common Stock is 17.09B
How many shares of Insmed Incorporated - Common Stock are outstanding?
Insmed Incorporated - Common Stock has 17B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.